Arrowpoint Investment Partners (Singapore) Pte. Ltd.
Long book
$67.3M
Q1 2026
Positions
76
Top-10 weight
50%
concentration
Last quarter
+23.4%
SPY +14.8%
Turnover
69%
of book per quarter
Strategy in plain words
auto-generated from filingsArrowpoint Investment Partners (Singapore) Pte. Ltd. is a quantitative fund whose holdings reflect models, not opinions, specialised in healthcare (74% of the long book), running a $67.3M US long book across 76 positions.
The portfolio is moderately concentrated (top 10 ≈ 50% of the book). Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: ALPHABET INC-CL A, ASE TECHNOLOGY HOLDING -ADR, IONIS PHARMACEUTICALS INC, NEUROCRINE BIOSCIENCES INC, AXSOME THERAPEUTICS INC.
Over the last 6 quarters its long book ran on average 1.6pp per quarter ahead of the S&P 500, beating the index in 3 of 6 quarters. Signal value of individual moves is limited — treat changes as weak evidence.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-8.0%
Q1 2025
+16.1%
Q2 2025
+11.6%
Q3 2025
+0.4%
Q4 2025
-6.3%
Q1 2026
+23.4%
Sector allocation
Healthcare 78%
Technology 18%
Financials 4%
Industrials 0%
Long book by quarter
What does Arrowpoint Investment own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| GOOGL ALPHABET INC-CL A | Technology | 31.1K | $9.0M | 13.3% | +2123.4% |
| IONS IONIS PHARMACEUTICALS INC | Healthcare | 39.0K | $2.9M | 4.4% | +55.8% |
| NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 21.6K | $2.8M | 4.2% | +512.9% |
| AXSM AXSOME THERAPEUTICS INC | Healthcare | 16.4K | $2.8M | 4.1% | +677.3% |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 48.7K | $2.8M | 4.1% | New |
| PTCT PTC THERAPEUTICS INC | Healthcare | 39.7K | $2.7M | 4.0% | +329.8% |
| PFE PFIZER INC | Healthcare | 71.3K | $2.0M | 3.0% | +64.5% |
| REGN REGENERON PHARMACEUTICALS | Healthcare | 2.5K | $1.9M | 2.9% | +62.7% |
| JNJ JOHNSON & JOHNSON | Healthcare | 7.9K | $1.9M | 2.9% | -97.5% |
| AMGN AMGEN INC | Healthcare | 4.9K | $1.7M | 2.6% | -17.2% |
| GILD GILEAD SCIENCES INC | Healthcare | 12.0K | $1.7M | 2.5% | -38.4% |
| VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 3.4K | $1.5M | 2.3% | +1.4% |
| UNH UNITEDHEALTH GROUP INC | Financials | 5.2K | $1.4M | 2.1% | New |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 3.9K | $1.2M | 1.8% | +85.2% |
| INSM INSMED INC | Healthcare | 7.0K | $1.1M | 1.7% | -39.3% |
| PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 9.3K | $984K | 1.5% | New |
| MRNA MODERNA INC | Healthcare | 17.1K | $869K | 1.3% | New |
| BIIB BIOGEN INC | Healthcare | 4.7K | $863K | 1.3% | +64.8% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 8.0K | $775K | 1.2% | +149.1% |
| OSG OCTAVE SPECIALTY GROUP INC | Financials | 139.2K | $647K | 1.0% | -31.4% |
| TWST TWIST BIOSCIENCE CORP | Healthcare | 13.5K | $640K | 1.0% | +34.9% |
| MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 1.2K | $624K | 0.9% | +221.3% |
| NTRA NATERA INC | Healthcare | 3.0K | $594K | 0.9% | New |
| AXGN AXOGEN INC | Healthcare | 16.3K | $539K | 0.8% | -15.3% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 13.8K | $531K | 0.8% | +87.5% |
| CYTK CYTOKINETICS INC | Healthcare | 7.4K | $487K | 0.7% | +64.9% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 5.8K | $430K | 0.6% | +97.8% |
| TNGX TANGO THERAPEUTICS INC | Healthcare | 20.5K | $428K | 0.6% | New |
| COO COOPER COS INC/THE | Healthcare | 5.9K | $422K | 0.6% | -43.5% |
| LLY ELI LILLY & CO | Healthcare | 442 | $407K | 0.6% | -95.2% |
| ERAS ERASCA INC | Healthcare | 24.8K | $402K | 0.6% | New |
| LITE LUMENTUM HOLDINGS INC | Technology | 562 | $395K | 0.6% | -95.1% |
| ILMN ILLUMINA INC | Healthcare | 3.0K | $373K | 0.6% | New |
| BIOA BIOAGE LABS INC | Healthcare | 20.8K | $364K | 0.5% | New |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 4.0K | $337K | 0.5% | -36.6% |
| IBRX IMMUNITYBIO INC | Healthcare | 41.0K | $315K | 0.5% | New |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 527 | $313K | 0.5% | New |
| DYN DYNE THERAPEUTICS INC | Healthcare | 17.2K | $312K | 0.5% | +19.7% |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 6.1K | $310K | 0.5% | -55.3% |
| TYRA TYRA BIOSCIENCES INC | Healthcare | 8.1K | $309K | 0.5% | New |
| ALMS ALUMIS INC | Healthcare | 12.0K | $265K | 0.4% | New |
| ORKA ORUKA THERAPEUTICS INC | Healthcare | 5.1K | $252K | 0.4% | New |
| EQH EQUITABLE HOLDINGS INC | Financials | 6.8K | $252K | 0.4% | New |
| SMMT SUMMIT THERAPEUTICS INC | Healthcare | 12.1K | $230K | 0.3% | New |
| NVST ENVISTA HOLDINGS CORP | Healthcare | 9.0K | $228K | 0.3% | -38.8% |
| CGON CG ONCOLOGY INC | Healthcare | 3.4K | $228K | 0.3% | New |
| DXCM DEXCOM INC | Healthcare | 3.6K | $228K | 0.3% | New |
| NKTR NEKTAR THERAPEUTICS | Healthcare | 2.8K | $204K | 0.3% | -42.6% |
| VSTM VERASTEM INC | Healthcare | 36.2K | $192K | 0.3% | New |
| CLYM CLIMB BIO INC | Healthcare | 24.6K | $168K | 0.3% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 82 | $112.5M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 11, 2026 | 104 | $678.7M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 79 | $100.1M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 13, 2025 | 63 | $112.6M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 13, 2025 | 903 | $843.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 18, 2025 | 737 | $487.4M | canonical | SEC ↗ |